AUSTIN, Texas, July 18, 2016 (GLOBE NEWSWIRE) - Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare diseases and cancer, today provided a regulatory and clinical update for its AEB1102 program. AEB1102, the company’s lead investigational molecule, is a recombinant human enzyme designed to degrade the amino acid arginine and is being developed to treat two extremes of arginine metabolism.
“We have developed a clinical program for AEB1102 with three ongoing clinical trials. The momentum for this program continues to build with AEB1102 receiving Fast Track designation from the FDA for hyperargininaemia in May and also receiving a positive opinion for Orphan Drug Designation from the European Medicines Agency this month,” said David G. Lowe, Ph.D., co-founder, president and chief executive officer at Aeglea. “We believe this molecule has great potential for patients with rare diseases and cancer, and we look forward to gathering critical data as we continue to advance our programs.”
Read more: https://globenewswire.com/news-release/2016/07/18/856717/0/en/Aeglea-BioTherapeutics-Provides-Update-on-AEB1102-Clinical-Program-in-Rare-Diseases-and-Cancer.html